World Conference on Lung Cancer Tuesday Press Conference: Improving the Cure Rate for Stage III Lung Cancer
TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Today’s press conference at the International Association for the Study of Lung Cancer’s (IASLC’s) 19th World Conference on Lung Cancer (WCLC) featured some of the year’s most innovative research in both small cell and non-small cell lung cancer. Frances Shepherd, M.D., FRCPC, WCLC honorary chair, medical oncologist at Princess Margaret Cancer Centre and former president of the IASLC (2005-2007), opened with the practice-changing importance of data shared this morning at the 2018 Presidential Symposium. Dr. Shepherd continued with background on the current inoperability and low cure rate of Stage III lung cancers, which comprise 1/3 of all lung cancers. Ground breaking data presented during today’s symposium demonstrated an advancement in disease treatment not seen for many years.
PACIFIC study shows durvalumab improves overall survival in patients with unresectable non-small cell lung cancer without progression after chemoradiotherapy
Recent findings from the PACIFIC trial found that durvalumab demonstrates statistically significant and clinically meaningful improvement in overall survival (OS) compared with placebo for patients with Stage III, unresectable non-small cell lung cancer (NSCLC) who have not progressed following chemoradiotherapy (CRT).
According to Scott J. Antonia, M.D., Ph.D., department chair of the Thoracic Oncology Department at the H. Lee Moffitt Cancer Center and Research Institute in Tampa and Professor of Oncologic Sciences at the University of South Florida College of Medicine, these results are significant, as PACIFIC is the first trial to show a survival advantage following CRT in this patient population.
“Results of PACIFIC provide compelling evidence for the unprecedented benefit of durvalumab treatment as the standard of care in this patient population,” said Dr. Antonia. “Durvalumab offers the first major advance in this disease setting in many years, offering new hope to patients with Stage III, unresectable NSCLC without progression after CRT.”
Read the full press release here.
Interim analysis of ALTA-1L demonstrates potential for brigatinib as first-line treatment option for ALK-positive non-small cell lung cancer
An interim analysis of the ALTA-1L study provided the first comparative data on the efficacy and safety of brigatinib versus crizotinib, the first-line standard of care comparator, in patients with anaplastic lymphoma kinase (ALK) inhibitor-naive ALK+ non-small cell lung cancer (NSCLC).
Lead investigator Ross Camidge, M.D., Ph.D., Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center, and team found one-year post-treatment, 67 percent of patients treated with brigatinib remained progression-free compared to 43 percent of those treated with crizotinib, and the risk of progression or death was reduced by 51 percent with brigatinib compared to crizotinib.
“Interim data shows brigatinib is set to become a first-line treatment option for ALK+ lung cancer,” said Dr. Camidge. “Even with only nine to 11 months of follow-up, the efficacy of brigatinib is clearly superior to crizotinib.”
Read the full press release here.
NELSON study shows CT screening for nodule volume management reduces lung cancer mortality by over fifty percent
Recent findings from Europe’s largest running lung cancer screening trial, the NELSON study, demonstrate that the use of computed tomography (CT) screening with a unique nodule management protocol led to a 26 percent reduction in deaths among lung cancer patients at eight years of study follow-up.
Harry J. De Koning, M.D., Ph.D., professor of Public Health & Screening Evaluation, Erasmus Medical Center, Rotterdam, Netherlands, and team initiated the study to assess the effect of CT screening, in combination with increasing screening intervals, on lung cancer mortality.
“These findings show that CT screenings are an effective way to assess and manage nodule volume in lung cancer patients, often leading to detection of suspicious nodules and subsequent surgical intervention, and can positively impact survival rates,” said Dr. De Koning. “These results can be used to inform and direct ongoing medical follow up and intervention for lung cancer patients.”
Read the full press release here.
Atezolizumab improves outcomes for small cell lung cancer when added to standard-of-care treatment
The IMpower133 study successfully met its co-primary endpoints, demonstrating that adding 1L atezolizumab to standard carboplatin and etoposide prolonged overall survival (OS) and progression-free survival (PFS) in patients with extensive-stage small cell lung cancer (ES-SCLC), as compared to carboplatin and etoposide treatment alone.
According to presenter Stephen V. Liu, M.D., associate professor of medicine at Georgetown University and a member of the trial steering committee, these findings have the potential to change the current treatment landscape for ES-SCLC.
“The standard of care for extensive-stage small cell lung cancer has been unchanged for decades, which has contributed to unacceptably poor outcomes,” said Dr. Liu. “This is the first study in 30 years to show a significant improvement in survival in the first line treatment of this highly lethal disease. This is an exciting time in oncology, and we are thrilled to finally see real progress in the SCLC space.”
Read the full press release here.
LUME-Meso study shows nintedanib plus pemetrexed/cisplatin does not improve progression-free or overall survival in patients with malignant pleural mesothelioma of epithelioid subtype
Findings from the LUME-Meso study demonstrate that triple angiokinase inhibitor nintedanib combined with standard-of-care pemetrexed/cisplatin does not impact progression-free survival (PFS) and overall survival (OS) for unresectable malignant pleural mesothelioma (MPM) patients with epithelioid histology.
When Phase II data of LUME-Meso showed patients with epithelioid histology derived the greatest benefit from nintedanib added to pemetrexed/cisplatin in terms of improved PFS versus placebo and a trend towards improved OS, Giorgio V. Scagliotti, M.D., Ph.D., of the University of Turin’s Department of Oncology and S. Luigi Hospital, president of the International Association for the Study of Lung Cancer (IASLC), and team amended the Phase III protocol to focus solely on this subgroup.
“Unfortunately, the Phase III results of LUME-Meso did not confirm that nintedanib in combination with pemetrexed/cisplatin prolongs patients’ lives,” said Dr. Scagliotti. “However, the trial reaffirms the need for solid confirmatory studies, adequately sized, to challenge the standard of care in advanced malignant mesothelioma.”
Read the full press release here.
Livestreams of the daily press conferences are available here.
About the WCLC
The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.
About the IASLC
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.
Contacts:
|
|
Lisa Rivero | Becky Bunn, MSc |
Vice President | Public Relations Manager |
lrivero@jpa.com| +1 617-657-1305 | Becky.Bunn@IASLC.org | +1 720-254-9509 |
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Prosafe SE: Operational Update - March 202419.3.2024 13:27:59 CET | Press release
Fleet utilization for February 2024 was 55.9 percent. Safe Notos, Safe Zephyrus and Safe Concordia had utilization of 100 percent in February. Safe Eurus had utilization of 91.3 percent in February due to a repair that was completed during the month. Safe Caledonia is laid up at Scapa Flow in the UK pending future work. Safe Boreas and Safe Scandinavia are laid up in Norway pending future work Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com Stavanger, 19 March 2024 Prosafe SE For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Inside Information: Manu Skyttä, new President and CEO of Aspocomp Group Plc, will assume his duties on May 20, 202419.3.2024 13:25:00 CET | Press release
Aspocomp Group Plc, Inside Information, March 19, 2024 at 2:25 p.m. “We are pleased that Manu Skyttä will take up his position as President and CEO of Aspocomp in May. With his character, competence and energy, Mr. Skyttä strengthens Aspocomp’s strategy as a trusted supplier of demanding circuit board technology to all Aspocomp customers. At this point, I would like to thank Mikko Montonen on behalf of the entire Board for his long-term commitment to Aspocomp,” says Päivi Marttila, Chair of Aspocomp’s Board. Manu Skyttä succeeds Mikko Montonen, who, as previously announced, has agreed with the Board of Directors to step down from the role of President and CEO of the company. Mr. Montonen has committed to staying on as the company's President and CEO until May 20, 2024. For further information, please contact Päivi Marttila, the Chair of the Board of Directors, tel. +358 40 028 5358. ASPOCOMP GROUP PLC Board of Directors Aspocomp – heart of your technology A printed circuit board (PCB)
Investeringsforvaltningsaftale med BI Management A/S er godkendt af Finanstilsynet19.3.2024 13:15:48 CET | pressemeddelelse
PFA Asset Management A/S offentliggjorde i selskabsmeddelelse af 22. januar 2024, at Investeringsforeningen PFA Invests (”Foreningen”) bestyrelse havde besluttet at udpege BI Management A/S som investeringsforvaltningsselskab for Foreningen. Finanstilsynet har godkendt valget af BI Management A/S som nyt investeringsforvaltningsselskab for Foreningen. BI Management A/S vil overtage rollen som investeringsforvaltningsselskab seneste ved udgangen af andet kvartal 2024. Eventuel henvendelse vedrørende denne meddelelse kan rettes til direktør Rasmus Bessing. Med venlig hilsen PFA Asset Management A/S Rasmus Bessing Direktør
Offentliggørelse af bestyrelsens redegørelse19.3.2024 13:05:00 CET | pressemeddelelse
Selskabsmeddelelse nr. 8-2023/24 19. marts 2024 MÅ IKKE OFFENTLIGGØRES, PUBLICERES ELLER UDLEVERES DIREKTE ELLER INDIREKTE I ELLER TIL NOGEN JURISDIKTION, HVOR DETTE VILLE UDGØRE EN OVERTRÆDELSE AF GÆLDENDE LOVGIVNING ELLER REGLER I DEN PÅGÆLDENDE JURISDIKTION, HERUNDER I USA Offentliggørelse af bestyrelsens redegørelse Med henvisning til InterMail A/S' ("InterMail") meddelelse af 5. marts 2024 (nr. 7-2023/24) om offentliggørelse af tilbudsdokumentet vedrørende det frivillige offentlige overtagelsestilbud på InterMail fremsat af CapHold 4 inv ApS ("Tilbuddet"), offentliggør InterMail i dag bestyrelsens redegørelse om Tilbuddet ("Redegørelsen") i henhold til § 22 i bekendtgørelse nr. 636/2020 om overtagelsestilbud. Redegørelsen indeholder bestyrelsens holdning til tilbuddet og begrundelsen herfor, herunder bestyrelsens holdning til konsekvenserne for alle selskabets interessenter og til tilbudsgivers strategiske planer for målselskabet samt disses sandsynlige konsekvenser for beskæftige
Zoom Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 202419.3.2024 13:04:05 CET | Press release
SAN JOSE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Zoom Video Communications, Inc. (NASDAQ: ZM), has been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2024. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. These organizations are setting new standards and achieving remarkable milestones in all sectors of the economy. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 606 organizations across 58 sectors and regions. “At Zoom, we continue to innovate rapidly and are doubling down on our commitment to offering an AI-powered collaboration platform that delivers limitless human connection, reimagines teamwork, and strengthens customer connections,” said Smita Hashim, chief product officer at Zoom. “Fast Company’s recognition further validates our mission and dedication to providing our customers with choice and a high-quality, open collaboration platform power